Arovella Therapeutics Limited ASX: ALA Share Price & Review

ALA Overview

ALA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ALA

Website

Arovella Therapeutics Limited

Telephone

61.3.9824.5254

Address

Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$180.10M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.21

Trade Value (12mth)

AU$63,022.00

1 week

9.09%

1 month

-2.7%

YTD

50%

1 year

56.52%

All time high

14.78

Key Fundamentals

EPS 3 yr Growth

-38.80%

EBITDA Margin

Operating Cashflow

-$7m

Free Cash Flow Return

-92.10%

ROIC

-116.60%

Interest Coverage

-1,247.60

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

978m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date	Announcements
06 December 24	Release of Shares from Escrow × Release of Shares from Escrow
29 November 24	Change of Director's Interest Notice x5 × Change of Director's Interest Notice x5
26 November 24	Notification regarding unquoted securities - ALA × Notification regarding unquoted securities - ALA
15 November 24	AGM Chairman's Address and CEO & MD Presentation × AGM Chairman's Address and CEO & MD Presentation
15 November 24	Results of Annual General Meeting × Results of Annual General Meeting
15 November 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
15 November 24	Notice Under Section 708A × Notice Under Section 708A
13 November 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
13 November 24	Notice Under Section 708A × Notice Under Section 708A
29 October 24	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
29 October 24	AusBioInvest Presentation × AusBioInvest Presentation
25 October 24	Arovella receives R&D tax rebate of $3.0 million × Arovella receives R&D tax rebate of $3.0 million
24 October 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
24 October 24	Notice Under Section 708A × Notice Under Section 708A
18 October 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
18 October 24	Notice Under Section 708A × Notice Under Section 708A
16 October 24	Investor Presentation × Investor Presentation
16 October 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
16 October 24	Notice Under Section 708A × Notice Under Section 708A
14 October 24	Clinical Advisory Board established × Clinical Advisory Board established
09 October 24	Notice of Annual General Meeting/Proxy Form × Notice of Annual General Meeting/Proxy Form
07 October 24	Notification regarding unquoted securities - ALA × Notification regarding unquoted securities - ALA
01 October 24	Release of Shares from Escrow × Release of Shares from Escrow
19 September 24	Application for quotation of securities - ALA × Application for quotation of securities - ALA
19 September 24	Notification regarding unquoted securities - ALA × Notification regarding unquoted securities - ALA

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

What is the current share price of Arovella Therapeutics Limited (ALA:ASX)?

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.17.

What is the 52-week high share price for Arovella Therapeutics Limited (ALA:ASX)?

The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.21.

What is the 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)?

The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.10.

What is the dividend yield for Arovella Therapeutics Limited (ALA:ASX)?

Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.

What was Arovella Therapeutics Limited (ALA:ASX) last dividend payment?

Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.

What is the franking level for Arovella Therapeutics Limited (ALA:ASX)?

Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.

In which sector is Arovella Therapeutics Limited (ALA:ASX) classified?

Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.

The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .

Company

Important

Get the latest insights and hot tips delivered right to your inbox

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.17

ALA Overview

ALA Health Scores

About ALA

ALA Price Chart

Key Stats

AU$180.10M

N/A

N/A

Dividends Overview

N/A

N/A

N/A

Market Data

Key Fundamentals

Other Data

ALA Announcements

Latest Announcements

Release of Shares from Escrow

Change of Director's Interest Notice x5

Notification regarding unquoted securities - ALA

AGM Chairman's Address and CEO & MD Presentation

Results of Annual General Meeting

Application for quotation of securities - ALA

Notice Under Section 708A

Application for quotation of securities - ALA

Notice Under Section 708A

Quarterly Activities/Appendix 4C Cash Flow Report

AusBioInvest Presentation

Arovella receives R&D tax rebate of $3.0 million

Application for quotation of securities - ALA

Notice Under Section 708A

Application for quotation of securities - ALA

Notice Under Section 708A

Investor Presentation

Application for quotation of securities - ALA

Notice Under Section 708A

Clinical Advisory Board established

Notice of Annual General Meeting/Proxy Form

Notification regarding unquoted securities - ALA

Release of Shares from Escrow

Application for quotation of securities - ALA

Notification regarding unquoted securities - ALA

Dividends

Key Stats

N/A

N/A

N/A

N/A

Values and Recommendations

Key Stats

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

0.00%

0

N/A

N/A

N/A

N/A

Discover Short-sellingOpportunities

ALA Shortsell

Related Companies

Frequently Asked Questions

Company

Company

Important

Discover
Short-selling
Opportunities